CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
序贯而非挽救
英文原题：Sequence not salvage.
查看英文原题
Sequence not salvage.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞治疗从根本上改变了多发性骨髓瘤（MM）复发/难治性疾病的治疗格局，但MM仍无法治愈。两种CAR-T 产品idecabtagene vicleucel（ide-cel；Abecma）和ciltacabtagene autoleucel（cilta-cel；Carvykti）已获FDA和EMA批准用于治疗复发/难治性MM（RRMM）；两者均靶向在MM细胞上高表达的表面糖蛋白BCMA。CAR-T 治疗虽可带来深度且持久的应答，但多数患者仍需后续治疗，目前最佳后续治疗方案尚不明确。本文评述Liu等的研究：接受BCMA特异性CAR-T 治疗后接受挽救治疗的多发性骨髓瘤患者结局——LEGEND-2回顾性分析。Br J Haematol. 2024;204:1780–1789。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of multiple myeloma (MM) has fundamentally changed the relapsed and refractory therapeutic landscape, but the disease remains incurable. Two CAR-T products, idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti), have been FDA- and EMA-approved for the treatment of relapsed/refractory MM (RRMM); both target B-cell maturation antigen (BCMA), a surface glycoprotein highly expressed on MM cells.
Despite deep and durable responses following CAR-T therapy, most patients will need subsequent treatment, and the optimal next-line therapy is presently unclear. Commentary on: Liu et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2. Br J Haematol 2024;204:1780-1789.
论文信息
- 作者
- Sborov DW、Fortuna GG、Hayden PJ
- 第一作者单位
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, USA.United States
- 通讯作者单位
- Department of Haematology, School of Medicine, St. James's Hospital, Trinity College, Dublin, Ireland.Ireland
- 期刊
- British journal of haematology2024 May
- 原文标识
- PubMed 38563345 · DOI 10.1111/bjh.19439